August 22, 2018
Metastasizing brain tumor start-up Cereius lands $6M+
Cereius, Inc., a School of Medicine and School of Engineering start-up company developing novel approaches to treat solid tumor brain metastases, closed a $6.75m financing.
Cereius was founded by Dr. Michael Zalutsky and Dr. Kimberly Blackwell. Dr. Zalutsky is Professor of Radiology, Radiation Oncology and Biomedical Engineering at Duke University. Dr. Blackwell is Vice President, Early Phase Development and Immuno-oncology at Lilly Oncology and Adjunct Professor of Medicine, Duke University. Ed Field is CEO of Cereius which operates out of BioLabs North Carolina, a co-working space for life science startups in downtown Durham.
The Duke spinout has acquired $6.75 million in equity financing, with $6.5 million Series A round led by BioInnovation Capital, to include several individual investors. Cereius has received an additional $250,000 loan from the North Carolina Biotechnology Center.
Cereius is working on solutions to solid tumor brain metastasis developed from cancer cells growing in other parts of the body, such as breast cancer. 30% of advanced solid tumor patients developing brain metastasis represents between 100,000-170,000 patients/year in the US.
Read more about this story here: